When is "not that great" good enough? Well, how about when people expect things to be pretty bad? When that happens, "not that great" starts looking pretty good.
While overall U.S. sales were flat, U.S. pharmaceutical sales were up 1%, as were overall global pharmaceutical sales. Plavix, which is co-marketed with Sanofi-Aventis
Like the performance of the two Snow Whites (Plavix and Pravachol), the performance of the Dwarves was also mixed. Newer drugs such as Reyataz, Abilify, and Erbitux continue to grow nicely, but many other lesser drugs continue to stagger off into the sunset.
Unlike some pharmaceutical companies, Bristol-Myers' non-prescription-drug businesses actually matter. Sales from the nutritionals business climbed 7% to $548 million, while the company's other health-care businesses (imaging, over-the-counter medicines, and such) were flat at $455 million.
The story at Bristol-Myers continues to be "hurry up and wait." High-potential new drugs such as Pargluva -- to be marketed with Motley Fool Income Investor recommendation Merck
Part of the "hurry up and wait" also involves the impact of losing major drugs to generics. Pravachol will go off in 2006, and the fate of Plavix is still unknown as litigation concerning Sanofi's patents (and rights to exclusivity) is under way. Obviously, losing both of these drugs in a short span of time would be painful.
At least investors can't say they're not getting paid to be patient. While Bristol-Myers continues to look toward 2007 as the target for a resumption of growth, the company pays a healthy dividend that currently yields nearly 4.5%. I believe there are more exciting near-term growth stories in the pharmaceutical world, but I can't argue with collecting a solid dividend from a company that should still have brighter days ahead.
More Foolish pharmaceutical follies follow:
Looking to collect some solid dividends of your own? Let Mathew Emmert help you find the best stocks that pay you back by taking a trial subscription of the Motley Fool Income Investor newsletter.
More from The Motley Fool
Solar Companies Are Set Up for a Strong Earnings Season
Rising demand and prices for solar panel prices bode well for manufacturers.
Today's Workers Aren't Optimistic About Raises and Promotions, Data Shows
Surprisingly, a large number of workers across the globe think their chances of a pay or title boost are pretty low. Here's how to bust out of that cycle and propel your career forward.
Could These High-Flying Tech Stocks Start Paying a Dividend?
Alphabet, Facebook, and Adobe don't do it yet, but that could change sooner than you think.